Liraglutide lowered blood pressure and kidney markers in meta-analyses

All three papers are secondary research. A meta-analysis pools results from separate trials, and a systematic review collects every study that meets a preset rule. The table below lists the population, comparison, and main result for each review.

The next sections explain each one.

The strongest finding was that liraglutide lowered systolic blood pressure, the pressure in arteries when the heart pumps, in people with type 2 diabetic kidney disease, the kidney damage that can follow long-term type 2 diabetes ². The review pooled 23 randomized trials with 1,723 participants. People assigned to liraglutide had systolic blood pressure 5.00 mmHg lower than people in the control group, with a confidence interval from -7.17 to -2.84, meaning the true effect likely falls in that range. Diastolic blood pressure, the pressure between beats, did not clearly change ². Kidney markers moved in a favorable direction: creatinine, a waste product the kidneys filter, fell, and the urine albumin-to-creatinine ratio, a measure of protein leakage, also fell. Estimated filtration rate, a measure of how well the kidneys filter, rose. These are lab markers rather than clinical events such as needing dialysis, so the review does not show whether liraglutide changes the chance of long-term kidney failure ². The same review also found improvements in blood sugar, blood fats, body mass index, and markers of inflammation, though those were secondary observations ².

In women with PMOS, adding liraglutide to metformin produced a small drop in fasting blood glucose and a rise in SHBG, but more nausea than metformin alone ³. PMOS stands for polyendocrine metabolic ovarian syndrome, the condition formerly called PCOS, and it can include irregular periods and hormone imbalances. The review pooled randomized trials that compared liraglutide plus metformin with metformin alone. Fasting blood glucose was 0.19 mmol/L lower in the combination group, a modest change ³. SHBG, short for sex hormone binding globulin, a protein that carries hormones in the blood, rose by 7.89 units ³. That may change how much testosterone is free in the blood, which matters in PMOS, but the review did not measure clinical outcomes such as ovulation or pregnancy. Nausea was clearly more common with the combination: the risk was 8.30 times higher than with metformin alone, with a wide interval from 2.64 to 26.10, which reflects uncertainty because few studies were pooled ³.

A systematic review of 101 studies found that injection-site reactions were most common with tirzepatide, then liraglutide, and less common with semaglutide ⁴. Injection-site reactions include redness, itching, or bleeding where the shot went in. They were generally mild, and the risk appeared to rise with dose. The review did not give a single liraglutide rate, so the ranking matters more than the absolute number. A different skin sensation called dysesthesia, meaning unusual feelings such as tingling or burning, was most strongly linked to semaglutide. It occurred in roughly 5% of people at standard doses and up to 20% at the higher weight-management dose ⁴. Rare severe immune skin conditions were also reported across these medicines ⁴. The 101 studies included randomized trials, observational studies, safety database analyses, and case reports ⁴.

These new papers fit a wider picture of liraglutide. For weight loss in adults with overweight or obesity, a large meta-analysis of 69 randomized trials places liraglutide above placebo ⁵. In type 2 diabetes, trials show that HbA1c, a measure of average blood sugar over several months, falls by roughly 1.6 to 1.8 percentage points ⁶. A large cardiovascular outcomes trial called LEADER found fewer major cardiovascular events and deaths ⁸. Separate research in fatty liver found improvements in liver fat ⁹. So the blood-pressure and kidney-marker changes in the new meta-analysis are consistent with a drug that has measurable effects beyond blood sugar ². The PMOS review adds a small amount of evidence in a less studied population ³, and the skin review is a reminder that side effects include more than nausea ⁴. Existing safety data already showed that nausea, vomiting, and diarrhea are the most common issues, especially early in treatment ¹⁰.

The kidney review measured lab markers, not clinical events such as needing dialysis or developing kidney failure ². The evidence does not establish that liraglutide changes those long-term outcomes. The PMOS meta-analysis had few studies and a wide nausea risk interval, so the true nausea risk is uncertain ³. The skin review collected reports and studies, but it was not a randomized comparison, so it cannot establish how often each drug causes reactions in matched people ⁴. The evidence also does not establish how liraglutide compares with semaglutide or tirzepatide on these outcomes, because these papers did not include that direct comparison ².